RFX5 antibody

Catalog No. ABIN2461622

Product Details anti-RFX5 Antibody

Target: RFX5 (Regulatory Factor X 5 (RFX5))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This RFX5 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Purification: Antibody is purified by peptide affinity chromatography method.

Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human RFX5.

Application Details

Application Notes: RFX5 antibody can be used for detection of RFX5 by ELISA at 1:62500. RFX5 antibody can be used for detection of RFX5 by western blot at 2 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50,000 - 100,000.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Add 50 ?L of distilled water. Final antibody concentration is 1 mg/mL.

Concentration: 1 mg/mL

Buffer: Antibody is lyophilized in PBS buffer with 2 % sucrose.

Handling Advice: As with any antibody avoid repeat freeze-thaw cycles.

Storage: 4 °C/-20 °C

Storage Comment: For short periods of storage (days) store at 4 °C. For longer periods of storage, store RFX5 antibody at -20 °C.

Target Details for RFX5

Target: RFX5 (Regulatory Factor X 5 (RFX5))

Alternative Name: RFX5 (RFX5 Products)

Synonyms: regulatory factor X5 antibody, regulatory factor X, 5 (influences HLA class II expression) antibody, RFX5 antibody, Rfx5 antibody

Background: RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. RFX is a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.A lack of MHC-II expression results in a severe immunodeficiency syndrome called MHC-II deficiency, or the bare lymphocyte syndrome (BLS, MIM 209920). At least 4 complementation groups have been identified in B-cell lines established from patients with BLS. The molecular defects in complementation groups B, C, and D all lead to a deficiency in RFX, a nuclear protein complex that binds to the X box of MHC-II promoters. The lack of RFX binding activity in complementation group C results from mutations in the RFX5 gene encoding the 75-kD subunit of RFX (Steimle et al., 1995). RFX5 is the fifth member of the growing family of DNA-binding proteins sharing a novel and highly characteristic DNA-binding domain called the RFX motif. Multiple alternatively spliced transcript variants have been found but the full-length natures of only two have been determined.

Molecular Weight: 65 kDa

Gene ID: 5993

NCBI Accession: NP_000440

UniProt: P48382